
Gallbladder cancer is an aggressive biliary tract malignancy and lymph node status is among the strongest determinants of outcome. For decades, the surgical debate has focused on the extent of lymphadenectomy and on whether para-aortic or interaortocaval nodal involvement should be regarded as regional extension or systemic disease. This binary framing is useful for staging but anatomically incomplete. Classical lymphatic studies described three drainage routes: cholecysto-celiac, cholecysto-retropancreatic and cholecysto-mesenteric. These pathways involve stations 12, 8, 9, 13, 17 and 14 before converging toward station 16, especially 16a2 and 16b1. Current Western algorithms often focus on the hepatoduodenal ligament and treat para-aortic/interaortocaval nodal disease as a contraindication to curative-intent surgery. This Opinion Review proposes a pathway-aware framework for interpreting lymphadenectomy after neoadjuvant therapy. The concept is hypothesis-generating, not a validated therapeutic recommendation. For staging, reporting and research purposes, nodal assessment may be described by both nodal yield and station distribution; a six-node harvest limited to station 12 provides different anatomical information from a six-node harvest sampled across celiac, retropancreatic, mesenteric and para-aortic convergence basins. We do not advocate indiscriminate extended lymphadenectomy. Rather, in medically fit patients with adequate physiological reserve, no systemic progression and realistic R0 resection, pathway mapping and selective clearance may be discussed as an expert-center investigational framework. The key question is whether the involved pathway remains surgically controllable after biological selection, not simply whether station 16 is regional or metastatic.
Xanthogranulomatous cholecystitis (XGC) is a rare benign inflammatory disorder that can closely resemble gallbladder carcinoma (GBC) clinically, radiologically, intraoperatively, and even on gross pathological examination. This overlap may lead to both unnecessary radical surgery and undertreatment of unsuspected malignancy. This review summarizes the contemporary literature together with institutional clinical and radiological experience, focusing on diagnostic pitfalls and practical surgical decision-making. Two illustrative cases are also presented. Reliable preoperative differentiation between XGC and GBC remains difficult because symptoms, laboratory findings, tumor markers, and individual imaging features overlap considerably. A pattern-based interpretation of computed tomography and magnetic resonance imaging findings may improve diagnostic confidence. Diffuse wall thickening, continuous mucosal enhancement, intramural hypoattenuating or T2-hyperintense nodules, gallstones, and preservation of the mural architecture tend to favor XGC, whereas focal mass formation, mucosal disruption, biliary obstruction, lymphadenopathy, and convincing hepatic invasion raise greater concern for GBC. Machine-learning and deep-learning models have shown promising diagnostic performance, although external validation and improved interpretability are still required before they can be incorporated into routine clinical practice. Frozen-section analysis, careful nodal assessment, and delayed oncologic resection after definitive histological assessment when uncertainty persists may provide a reasonable balance between avoiding unnecessary radical procedures and preventing undertreatment of true malignancy.
Owing to its unique tolerogenic immune microenvironment, the liver can confer substantial immunologic protection on concurrently transplanted allogeneic grafts in combined organ transplantation. This review summarizes the molecular and cellular mechanisms underlying liver-mediated immunoprotection, including antigen presentation by liver sinusoidal endothelial cells and tolerogenic dendritic cells, enrichment of regulatory T cells, clonal deletion of donor-reactive T cells, clearance of donor-specific antibodies, and the establishment of microchimerism. We further synthesize clinical outcome data from combined liver-intestinal transplantation and multivisceral transplantation, and evaluate the translational potential of optimized immunosuppressive strategies, cell-based therapies, and emerging technologies such as normothermic machine perfusion. Although current evidence supports the immunoprotective role of the liver, its precise molecular mechanisms remain incompletely defined and require further validation. Prospective multicenter studies are also warranted.